Tianjin Pharmaceutical Da Ren Tang's (SGX:T14, SHA:600329) net profit attributable to owners of the parent declined 3% during the first quarter of the year to 374.2 million yuan from 387.3 million yuan a year earlier, according to a filing with the Singapore Exchange on Tuesday.
Earnings per share dropped to 0.49 yuan compared with 0.50 yuan in the comparable period.
Revenue declined 30% year over year to 1.46 billion yuan from 2.09 billion yuan, due to a change in the consolidation scope which excluded data from Tianjin Zhongxin Medicine.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。